Form 4: UTHR CEO Rothblatt Exercises, Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised and sold common stock options totaling 8,000 shares over two days as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed transactions involving the exercise of stock options and subsequent sale of common stock on October 15 and October 16, 2025.
• On October 15, 2025, Rothblatt exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Immediately following the exercise on October 15, 2025, Rothblatt sold 4,000 shares of common stock in multiple trades at weighted average prices ranging from $433.42 to $436.4721.
• On October 16, 2025, Rothblatt again exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Following this exercise on October 16, 2025, Rothblatt sold 4,000 shares of common stock in multiple trades at weighted average prices ranging from $430.2253 to $432.86.
• All transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• After these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 644,359 shares through various family trusts and spouse.
• The number of beneficially owned stock options decreased from 182,000 to 178,000 after the October 16, 2025 transactions.

Sentiment

Score: 6

Explanation: The transactions are part of a pre-arranged 10b5-1 trading plan, which mitigates concerns about opportunistic insider selling. The executive realized substantial gains from exercising options at a much lower price than the sale price, reflecting past company performance and option value.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured approach to managing equity holdings rather than a reaction to immediate market conditions.
• The exercise price of $120.26 for the stock options is significantly lower than the sale prices (ranging from $430.2253 to $436.4721), indicating substantial unrealized gains on the options.

Negatives

• The sale of 8,000 shares by a key executive, even under a 10b5-1 plan, represents a reduction in direct insider ownership, which some investors might interpret cautiously.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.

Industry Context

This filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector, but rather reflects an executive's personal equity management strategy.

Related Party Transactions

• Shares are held indirectly in various family trusts where the Reporting Person and/or immediate family members are beneficiaries, or where the spouse is a trustee/beneficiary. These represent related party holdings.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be viewed by some as a slight reduction in insider alignment, though the pre-planned nature often lessens this concern. The significant profit realized by the executive from options exercise highlights the value creation for long-term option holders.

Next Steps

• Continuation of the 10b5-1 trading plan until the earlier of the exhaustion of 294,000 stock options (expiring March 15, 2026) or December 31, 2025.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 plan, which are generally not indicative of a change in the company's fundamental outlook or a signal for immediate investment action. The transactions reflect an executive's personal financial planning rather than a directional view on the stock. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions rather than this specific insider filing.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, SEC Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Common Stock, Executive Compensation, Biotechnology